Bavarian Nordic Announces 2014 Full Year Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bavarian Nordic Announces 2014 Full Year Results

KVISTGAARD, Denmark, March 11, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million / USD 175 million in 2013). The Group recorded an EBIT of DKK 17 million / USD 2 million (DKK 33 million / USD 5 million in 2013) and a net profit of DKK 26 million / USD 4 million (DKK 47 million loss / USD 7 million loss). Revenue and results were in line with the expectations for the year. At year-end 2014, the cash preparedness was DKK 1,000 million / USD 144 million (DKK 652 million / USD 94 million as of 31 December 2013). For 2015, Bavarian Nordic expects revenue at the level of DKK 1,000 million / USD 144 million and a break even result before interest and tax (EBIT). The cash preparedness at year-end is expected to be in the level of DKK 1,100 million / USD 159 million. Danish kroner (DKK) is the Company's functional currency. For convenience, the Company presents selected figures in USD above. These are based on a USD/DKK exchange rate of 6.9395, which is the official exchange rate of Danmarks Nationalbank, the central bank of Denmark, on March 10, 2015. Consolidated key financial figures are found at the end of this announcement. The full financial statements for 2014 are available in the annual report which can be downloaded from the Company's website: www.bavarian-nordic.com. Paul Chaplin, President & CEO of Bavarian Nordic, said: "2014 was a strong year for Bavarian Nordic where we met our financial and operational targets and even exceeded our own expectations, as new opportunities surfaced during the year. Our technology has received strong recognition by the closing of important deals, with Johnson & Johnson and Bristol-Myers Squibb, two industry leaders, in each of our business areas. We are in a transitional phase, preparing for expanding the pipeline in areas of unmet medical needs, while also continuing our efforts to expand our manufacturing capabilities that allows us to deliver according to current and future supply agreements." Significant achievements in 2014 and up to the reporting date * The U.S. Government exercised an option valued at USD 118 million for additional 4 million doses of IMVAMUNE smallpox vaccine, bringing the total number of doses delivered to-date to 28 million. * The U.S. Government also exercised an option valued at almost USD 22 million under the existing development contract for freeze-dried IMVAMUNE to fund the transfer of the validated manufacturing process to a commercial manufacturing line with a larger capacity. * Contracts were signed with the Canadian Government for the delivery of more than 60,000 doses of IMVAMUNE with options for up to an additional 450,000 doses. * A licensing and supply agreement was entered with Janssen on MVA-BN® Filo vaccine, which is being investigated in a prime-boost regimen with Janssen AdVac® vaccine against Ebola. The agreement has a potential value of up to USD 187 million and includes an equity investment in Bavarian Nordic. Janssen furthermore obtained an exclusive option to collaborate on MVA-BN in three additional infectious disease targets. * A first-in-human trial investigating MVA-BN Filo as an Ebola vaccine was initiated. * Enrollment was completed in the phase 3 study of PROSTVAC prostate cancer immunotherapy. 1,298 patients were enrolled in more than 200 centers across 15 countries. * Two new programs were added to the pipeline, both sponsored by our partner, the National Cancer Institute: A phase 2 combination study of CV-301 immunotherapy and BCG (Bacillus Calmette-Guerin) treatment was initiated in patients with bladder cancer and a phase 1 study of MVA-BN Brachyury (a tumor-associated antigen which is overexpressed in major solid tumor indications) was initiated in patients with advanced cancer * In February 2015, updated long-term survival data from an NCI sponsored combination study of PROSTVAC and Yervoy were presented. For patients receiving PROSTVAC and high doses of Yervoy, a median overall survival of 37.2 months was shown, compared to a predicted survival of 18.5 months. Furthermore, approximately 20% of these remain alive at 80 months. * In March 2015, Bavarian Nordic entered into an exclusive agreement with Bristol-Myers Squibb for PROSTVAC, under which the Company could receive up to USD 975 million, inclusive of USD 60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales. In addition, the companies will collaborate to explore the combination of PROSTVAC with agents from Bristol-Myers Squibb's immune- oncology portfolio. * Asger Aamund, founder and chairman of the board since the inception of Bavarian Nordic in 1994 stepped down. Gerard van Odijk, was elected the new chairman of the board. He has served as member of the board since 2008. * Paul Chaplin, Ph.D. was appointed President & CEO of Bavarian Nordic. He succeeded Anders Hedegaard who decided to seek new challenges outside the company after 7 years serving as CEO. Paul Chaplin has been with Bavarian Nordic for more than 15 years, the last 10 years as part of the executive management team. Selected upcoming milestones * Manufacture and deliver MVA-BN Filo vaccine to Janssen (targeting 2 million doses to contribute to the prime-boost regimen) (2015) * Initiation of Phase 2 and Phase 3 clinical trials of the Ebola prime-boost vaccine regimen * Potential new orders for MVA-BN Filo * Potential expanded collaboration with Janssen on additional infectious disease targets * Complete Phase 2 study of freeze-dried IMVAMUNE to support a pre-EUA submission (requirement for stockpiling) (2015) * Complete transfer of validated freeze-dried manufacturing process to a commercial scale facility (2015) * Secure IMVANEX/IMVAMUNE orders from rest of world * Investigational New Drug submission for MVA-BN RSV followed by initiation of Phase 1 study (H1, 2015) * Advance clinical studies exploring the therapeutic potential of PROSTVAC in combination with Yervoy and other potential checkpoint inhibitors as part of the clinical collaboration with Bristol-Myers Squibb * Finalize validation of the PROSTVAC commercial manufacturing process and prepare launch material * Interim analyses of the PROSTVAC Phase 3 clinical trial Webcast and conference call The Company will host a conference call today at 2.00 pm CET (9.00 am EDT). President and CEO, Paul Chaplin will present the annual results followed by a Q&A session with participation of the Company's executive management. Dial-in numbers for the conference call are: Denmark: +45 32 72 80 18, UK: +44 (0) 844 571 8957, USA: +1 866 682 8490. A webcast of the conference call will be broadcast simultaneously at http://www.bavarian- nordic.com/investor/events.aspx?event=4207. On this page, the accompanying presentation will be available prior to the conference call. Contacts Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43 Seth Lewis, Vice President Investor Relations (US). Phone + 1 978 341 5271 About Bavarian Nordic Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Consolidated Key Figures DKK million 2014 2013 2012 2011 2010 -------------------------------------------------------------------------------- Income statement Revenue 1,216.8 1,212.5 1,016.6 523.6  314.1 Production costs  495.1  484.7  513.6 403.4  444.5 Research and development costs  478.9  496.6  340.1 261.7 188.6 Distribution and administrative costs  226.1  197.8  194.6 166.8 155.1 Income before interest and tax (EBIT)  16.7  33.4 (31.7) (308.3) (474.1) Financial items, net  47.7  (27.2) (17.0)  11.9 (9.4) Income before company tax  64.4  6.2 (48.7) (296.4) (483.4) Net profit for the year  25.9  (46.7) (240.0) (268.4) (389.9) Balance sheet Total non-current assets  568.1  551.8  644.3 865.2  850.6 Total current assets 1,319.1  900.4  894.9 1,111.4  616.5 Total assets 1,887.3 1,452.2 1,539.2 1,976.6 1,467.1 Equity 1,252.1  976.3  999.7 1,207.6  810.4 Non-current liabilities  51.9  86.7  54.2 105.4  106.5 Current liabilities  583.3  389.3  485.3 663.6  550.2 Cash Flow Statement Securities, cash and cash equivalents  979.7  532.1  549.9  584.0  355.7 Cash flow from operating activities  338.7  147.1  20.1  (375.2)  (239.9) Cash flow from investment activities  (503.7)  (146.5)  71.0  (261.8)  (45.8) - Investment in intangible assets  (53.6)  (111.0)  (24.3)  (16.5)  (16.2) - Investment in property, plant and equipment  (52.4)  (44.4)  (20.9)  (31.2)  (45.7) Cash flow from financing activities  216.2  (7.1)  (9.6)  642.4  471.0 Financial Ratios (in DKK) (1)) Earnings (basic) per share of DKK 10  1.0  (1.8)  (9.2)  (12.1)  (25.7) Net asset value per share (historical)  45.2  37.4  38.3  46.3  62.5 Net asset value per share (adjusted) (2))  45.2  35.3  36.1  43.6  29.3 Share price at year-end (historical)  198  89  50  38  245 Share price at year-end (adjusted) (3))  198  89  50  38  190 Share price/Net asset value per share (historical)  4.4  2.4  1.3  0.8  3.9 Share price/Net asset value per share (adjusted) (2) +) (3))  4.4  2.5  1.4  0.9  6.5 Number of outstanding shares at year-end  27,671  26,094  26,094  26,094 12,962 Equity share 66% 67% 65% 61% 55% Number of employees, converted to full-time, at year-end 422 426 450 439 402 1) Earnings per share (EPS) are calculated in accordance with IAS 33 "Earning per share". Other financial ratios have been calculated in accordance with "Anbefalinger og Nøgletal 2010" (Recommendations and Financial ratios 2010) 2) Due to issue of new shares in 2014, net asset value per share for 2010-2013 have been recalculated based on outstanding shares at year-end 2014 3) Year-end share price for 2010 has been adjusted for rights issue in May 2011 [HUG#1901301]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 25

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 120

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 43

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 52

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Customer Care: Apivia and SoundHound Unite

Updated Category News Views 247

Transforming Customer Service with AI SoundHound AI (NASDAQ: SOUN) has joined forces with Apivia Courtage, a notable entity within France's AEMA Group, which is recognized as a leading mutual insurance organization. This partnership aims to implement agent-based artificial intelligence into Apivia Courtage's customer service systems through the innovative Amelia 7...

Continue Reading
Taiwan's Bold Pedal Into Sustainability: EUROBIKE 2026

Updated Category News Views 40

Stepping Up the Game at EUROBIKE 2026 Ask any veteran cyclist: The road to innovation is a winding one, and Taiwan's Bicycle Industry seems determined to tackle every curve head-on at EUROBIKE 2026. This isn't just about flashy tech; it's a full-blown commitment to smart, low-carbon mobility—a real 'get on the bike or get left behind' moment. Unveiling the AI-Powered...

Continue Reading
TDI Welcomes Jay Truesdale as New Chief Executive Officer

Updated Category News Views 389

TD International Appoints New Leadership TD International LLC (TDI), a prominent strategic advisory and risk intelligence firm, has announced significant leadership changes with the appointment of Jay Truesdale as Chief Executive Officer. This move marks a pivotal moment for TDI, as it looks to leverage Truesdale's considerable expertise in geopolitics and global markets....

Continue Reading
Canaan Inc. Streamlines Focus on Core Cryptocurrency Market

Updated Category News Views 258

Canaan Inc. Streamlines Focus on Core Cryptocurrency Market Canaan Inc. (NASDAQ: CAN) has recently taken a significant step in refining its business operations. The company is discontinuing its non-core AI semiconductor division to concentrate on its core strengths in the ever-evolving world of cryptocurrency. This strategic decision is aimed at enhancing efficiencies and...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 567

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading